Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
KROS
#2419
Keros Therapeutics, Inc. Common Stock
14.190
0
-3.14%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-3.14%
Aylık değişim
-21.86%
6 aylık değişim
-6.03%
Yıllık değişim
-6.03%
Önceki kapanış
14.650
0
Open
14.190
0
Bid
Ask
Low
14.190
0
High
14.190
0
Hacim
60
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
KROS
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
40.51 M
40.56 M
40.62 M
40.62 M
30.47 M
—
Valuation ratios
Enterprise value
1.82 B
82.2 M
-306.67 M
-148 M
-211.5 M
-583.97 M
Price to earnings ratio
-11.15
-3.17
-59.94
41.72
10.21
-11.18
Price to sales ratio
3 134.08
166.94
1.94
2.35
2.63
173.86
Price to cash flow ratio
14.42
3.68
1.44
2.55
3.51
11.18
Price to book ratio
1.17
1.04
0.17
0.21
0.23
1.65
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.09
0.07
0.19
0.04
0.01
0.31
Return on equity %
0.1
0.08
0.2
0.04
0.01
0.34
Return on invested capital %
—
710.18
1 604.14
361.25
139.94
2 815.51
Gross margin %
100
100
100
100
100
400
Operating margin %
15.12 K
1 750.62
71.99
219.16
108.92
2 150.7
EBITDA margin %
—
—
—
—
—
—
Net margin %
13.65 K
1 513.02
70.29
168.96
51.54
1 803.81
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
19.03
21.45
19.29
21.11
29.86
91.71
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.01
0.3
0.02
0.02
0.35
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.81
1.23
3.93
-0.73
0.08
4.51
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
14.12
14.96
17.57
16.99
17.07
66.59
Net current asset value per share
14.69
15.73
18.51
18.04
17.71
70
Tangible book value per share
14.17
15.27
17.77
17.4
17.32
67.76
Working capital per share
13.91
15
17.56
17.19
17.11
66.85
Book value per share
14.17
15.27
17.77
17.4
17.32
67.76
Haberler
Keros Therapeutics eski Lyell CFO’sunu yönetim kuruluna aldı
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Is KROS' KER-065 the Next Breakthrough in DMD Space?
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?